Skip to content

Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence

Community-based Monitoring of Cholera Antibodies' Seroprevalence, and Home Follow-up of Positive Cases, in the Context of Cholera Vaccination Campaign, Democratic Republic of the Congo

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05829772
Enrollment
7000
Registered
2023-04-26
Start date
2021-09-20
Completion date
2024-04-01
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cholera

Keywords

Cholera incidence rates, Mass vaccination campaign, V.Cholerae, Serial seroprevalence

Brief summary

This project aims to fill this essential knowledge gap by assessing the impact of oral cholera vaccine mass campaigns in 2 sites (urban and rural) in DRC, described in this protocol. The evidence generated from this project will be key to develop future strategies regarding cholera vaccine use in endemic settings, including places with higher burden in terms of cholera mortality

Detailed description

The project will comprise three different components: Clinical cholera surveillance to measure cholera diseases incidence in selected African hotspots targeted by vaccination. Serial serological surveys to measure the prevalence of recent cholera infection (within the last 12 months). Identification and follow up of individuals with positive V. cholerae shedding (symptomatic or asymptomatic) among sero-survey participants and among household members of cholera confirmed cases. The present protocol relates to the setup of seroprevalence surveys and the follow up of individuals with positive V. cholerae shedding identified through seroprevalence surveys, in DRC. This protocol will allow us to assess if a large vaccination campaign reaching high coverage in cholera hotspot in Africa can allow sustained control of cholera for at least two years, by fulfilling the following specific objectives: 1. To calculate the proportion of individuals infected with cholera recently (i.e. previous year or last 2 months) before the campaign distribution or in non-vaccinated zones (baseline survey, rural site) or following the mass OCV campaign and before the start of the usual cholera season (pre-season survey, urban site). 2. To assess proportion of individuals recently infected (i.e. infected in the last two months or in the last year) during the expected peak-week of cholera in the area (peak survey, urban site) and at the end of the expected cholera season (post-season survey), as compared to baseline or pre-season survey. 3. To assess the intra-household transmission and correlation in cholera recent infections among vaccinated and non-vaccinated households (post-season survey) 4. To compare mortality linked to diarrheal diseases and potential cholera in the community of rural site before and after vaccination 5. To assess the duration of shedding among vaccinated and unvaccinated individuals and the duration of viable V. cholerae in the peri-household environment. 6. To measure the secondary cholera attack rates (symptomatic and asymptomatic) at household level among vaccinated and unvaccinated individuals following the identification of an index case in a given household.

Interventions

None listed

Sponsors

Wellcome Trust
CollaboratorOTHER
Institut Pasteur
CollaboratorINDUSTRY
Institut National de Recherche Biomédicale. Goma, République Démocratique du Congo
CollaboratorUNKNOWN
Ministry of Public Health, Democratic Republic of the Congo
CollaboratorOTHER_GOV
Medecins Sans Frontieres, France
CollaboratorUNKNOWN
Epicentre
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* All persons, 1. Living in the randomly-selected households in targeted area AND 2. Randomly selected among household members. Inclusions will be limited to 1 participant per household, except for one survey AND 3. Giving his/her consent (or assent for children 13 to 17 years old) to participate in the study

Exclusion criteria

* People who decline to participate will be excluded from the study. For 2nd survey in Goma only: members of the household who cannot be reached after 2 attempts will be excluded.

Design outcomes

Primary

MeasureTime frameDescription
To better characterize cholera immunization in the population of cholera hotspot in Africa and assess the impact of a large vaccination campaign reaching high coverage2 yearsCholera-specific antibody levels will be measured in all participants for each surveys. Serial surveys will allow monitoring level of antibodies over time following the vaccination campaign

Secondary

MeasureTime frame
Assess proportion of individuals infected (the last 2 months or previous year) during the expected peak-week of cholera in the area and at the end of the expected cholera season (post-season survey), as compared to baseline or pre-season survey.2years
To assess the intra-household transmission and correlation in cholera recent infections among vaccinated and non-vaccinated households (post-season survey)2 years
Calculate proportion of individuals infected with cholera (previous year or last 2 months) before the campaign distribution or in non-vaccinated zones or following the massOCV campaign and before the start of cholera season:pre-season survey, urban site.2 years
To assess the duration of shedding among vaccinated and unvaccinated individuals and the duration of viable V. cholerae in the peri-household environment.2 years
To measure the secondary cholera attack rates (symptomatic and asymptomatic) at household level among vaccinated and unvaccinated individuals following the identification of an index case in a given household.2 years
To compare mortality linked to diarrheal diseases and potential cholera in the community of rural site before and after vaccination2 years

Countries

Democratic Republic of the Congo

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026